Sin‐Hua Moi
Impact in
- Molecular Medicine top 5%
- Antibiotic Resistance in Bacteria
- Nephrology top 5%
- Dialysis and Renal Disease Management
- Parathyroid Disorders and Treatments
Papers in
-
- Epigenetics and DNA Methylation 5
- Gene expression and cancer classification 4
-
- Breast Cancer Treatment Studies 7
- Cancer Genomics and Diagnostics 5
- Co-authors
- Li-Yeh Chuang (1 shared paper)Cheng‐Hong Yang (19 shared papers)Jin‐Bor Chen (18 shared papers)Li‐Yeh Chuang (14 shared papers)Yu‐Da Lin (8 shared papers)Ming‐Feng Hou (14 shared papers)Cheng-Hong Yang (10 shared papers)Ben‐Chung Cheng (4 shared papers)
In The Last Decade
Sin‐Hua Moi
55 papers receiving 614 citations
Peers
Comparison fields: 5 of 111
- Molecular Medicine 144
- Nephrology 116
- Endocrinology 71
- Applied Microbiology and Biotechnology 14
- Microbiology 24
Countries citing papers authored by Sin‐Hua Moi
This map shows the geographic impact of Sin‐Hua Moi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sin‐Hua Moi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sin‐Hua Moi more than expected).
Fields of papers citing papers by Sin‐Hua Moi
This network shows the impact of papers produced by Sin‐Hua Moi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sin‐Hua Moi. The network helps show where Sin‐Hua Moi may publish in the future.
Co-authors
The 25 scholars most cited alongside Sin‐Hua Moi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 58 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 184 | |
| 2 | 2021 | 39 | |
| 3 | 2020 | 28 | |
| 4 | 2016 | 24 | |
| 5 | 2016 | 23 | |
| 6 | 2019 | 22 | |
| 7 | 2019 | 20 | |
| 8 | 2020 | 20 | |
| 9 | De-glycosylated membrane PD-L1 in tumor tissues as a biomarker for responsiveness to atezolizumab (Tecentriq) in advanced breast cancer patients. | 2022 | 20 |
| 10 | 2016 | 17 | |
| 11 | 2017 | 16 | |
| 12 | 2020 | 14 | |
| 13 | 2018 | 13 | |
| 14 | 2016 | 12 | |
| 15 | 2017 | 10 | |
| 16 | 2018 | 9 | |
| 17 | 2021 | 8 | |
| 18 | 2016 | 8 | |
| 19 | 2023 | 8 | |
| 20 | 2022 | 7 |
About Sin‐Hua Moi
Sin‐Hua Moi is a scholar working on Molecular Biology, Cancer Research, Nephrology, Surgery and Oncology, having authored 58 papers that have together received 620 indexed citations. Recurring topics across this work include Dialysis and Renal Disease Management (13 papers), Breast Cancer Treatment Studies (7 papers), Cancer Genomics and Diagnostics (5 papers), Epigenetics and DNA Methylation (5 papers), Global Cancer Incidence and Screening (4 papers), Gene expression and cancer classification (4 papers), Iron Metabolism and Disorders (3 papers) and Muscle and Compartmental Disorders (3 papers). The work is most often cited by research in Molecular Medicine (144 citations), Nephrology (116 citations), Endocrinology (71 citations), Applied Microbiology and Biotechnology (14 citations) and Microbiology (24 citations). Sin‐Hua Moi has collaborated with scholars based in Taiwan, China and Czechia. Frequent co-authors include Li-Yeh Chuang, Cheng‐Hong Yang, Jin‐Bor Chen, Li‐Yeh Chuang, Yu‐Da Lin, Ming‐Feng Hou, Cheng-Hong Yang, Ben‐Chung Cheng, Fong‐Fu Chou and Fu Ou‐Yang. Their work appears in journals such as Scientific Reports, BMC Nephrology, Therapeutic Advances in Chronic Disease, International Journal of Molecular Sciences and BioMed Research International.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.